Journal Browser Advanced Search Help
Journal Browser Advanced search HELP
Korean J Lab Med. 2009 Aug;29(4):293-298. English. Original Article. https://doi.org/10.3343/kjlm.2009.29.4.293
Roh KH , Kim S , Kim CK , Yum JH , Kim MS , Yong D , Lee K , Kim JM , Chong Y .
Department of Laboratory Medicine, Korea University College of Medicine, Seoul, Korea.
Department of Laboratory Medicine and Research Institute of Bacterial Resistance, Yonsei University College of Medicine, Seoul, Korea.
Brain Korea 21 for Medical Sciences, Yonsei University College of Medicine, Seoul, Korea.
Korean Institute of Tuberculosis, Seoul, Korea.
Department of Clinical Laboratory Science, Dongeui University, Busan, Korea.
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Abstract

BACKGROUND: Bacteroides fragilis group organisms are the most frequently isolated anaerobes in human infections. Increasing resistance to various antimicrobial agents is a significant problem in choosing appropriate antimicrobial agents to treat anaerobic infections. Periodic monitoring of the regional resistance trends of B. fragilis group isolates is needed. METHODS: A total of 466 nonduplicate clinical isolates of B. fragilis group organisms (276 B. fragilis, 106 Bacteroides thetaiotaomicron, and 84 other B. fragilis group organisms) were collected during the 8-yr period from 1997 to 2004 in a Korean university hospital. Minimum inhibitory concentrations to various antimicrobial agents were determined by the CLSI agar dilution method. RESULTS: Eight isolates were resistant to imipenem. Additionally, the resistance rates to cefotetan were decreased in B. thetaiotaomicron, while those for clindamycin were significantly increased compared to the rates found in previous studies. Depending on species, resistance rates were 1-4% for imipenem, 1-6% for piperacillin-tazobactam, 4-11% for cefoxitin, 33-49% for piperacillin, 14-60% for cefotetan, and 51-76% for clindamycin. No isolates were resistant to chloramphenicol or metronidazole. CONCLUSIONS: Piperacillin-tazobactam, cefoxitin, imipenem, chloramphenicol, and metronidazole are still active against B. fragilis group isolates, while clindamycin no longer has a value as an empirical therapeutic agent in Korea. Furthermore, this study identified the first imipenem-resistant B. fragilis group isolates in Korea.

Copyright © 2019. Korean Association of Medical Journal Editors.